Original Article

Pediatric Nephrology

, Volume 25, Issue 5, pp 883-888

Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome

  • Zhihui LiAffiliated withDepartment of Nephrology, Hunan Children’s Hospital Email author 
  • , Cuirong DuanAffiliated withDepartment of Nephrology, Hunan Children’s Hospital
  • , Jinhua HeAffiliated withDepartment of Nephrology, Hunan Children’s Hospital
  • , Tianhui WuAffiliated withDepartment of Nephrology, Hunan Children’s Hospital
  • , Mai XunAffiliated withDepartment of Nephrology, Hunan Children’s Hospital
  • , Yi ZhangAffiliated withDepartment of Nephrology, Hunan Children’s Hospital
  • , Yan YinAffiliated withDepartment of Nephrology, Hunan Children’s Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Treating children with steroid-resistant nephrotic syndrome (SRNS) has been a clinical challenge for pediatricians. We recruited 24 children (18 boys and six girls) with steroid-resistant idiopathic nephrotic syndrome (SRINS) who were <2 years. All patients were administered prednisone 2 mg/kg per day prior to mycophenolate mofetil (MMF). By the end of the eighth week, MMF was initiated at 25–30 mg/kg daily for 6− 12 months. Prednisone dose was reduced stepwise. Biochemical assays were performed every 2 months. Complete remission was achieved in 15 patients, partial remission in six, and no response to MMF was noted in three. With MMF treatment, the levels of urinary protein and serum cholesterol decreased and that of serum albumin increased in a time-dependant manner. We demonstrated the MMF could reduce proteinuria in SRINS children <2 years. Our study suggests that MMF therapy might be an effective strategy for treating SRINS in children <2 years.

Keywords

Mycophenolate mofetil Steroid-resistant Idiopathic nephrotic syndrome Children